ArticleBMC infectious diseases2017
Outbreak of Middle East respiratory syndrome coronavirus in Saudi Arabia: a retrospective study.
Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rate of Intensive Care Unit admission and outcomes among patients with coronavirus: A systematic review and Meta-analysis.PloS one · 2020Pooled it
- A One Health Perspective on Camel Meat Hygiene and Zoonoses: Insights from a Decade of Research in the Middle East.Veterinary sciences · 2024Review
- Article
- Health Workers' Knowledge and Attitude towards Monkeypox in Southwestern Saudi Arabia: A Cross-Sectional Study.Diseases (Basel, Switzerland) · 2023Article
- Endothelial Dysfunction in SARS-CoV-2 Infection.Biomedicines · 2022Review
- Programmable Biosensors Based on RNA-Guided CRISPR/Cas Endonuclease.Biological procedures online · 2022Review
- Review
- Cross fertilisation of Public Health and Translational Research.Journal of the Indian Institute of Science · 2022Review
- Exploring the Lethality of Human-Adapted Coronavirus Through Alignment-Free Machine Learning Approaches Using Genomic Sequences.Current genomics · 2021Article
- CPMPARISON between COVID-19 and MERS demographic data in Saudi Arabia: a retrospective study.The Libyan journal of medicine · 2021Article
- SARS-CoV-2 at the human-animal interphase: A review.Heliyon · 2021Review
- GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics.Pharmacological research · 2021Review
- Genetic Insights into the Middle East Respiratory Syndrome Coronavirus Infection among Saudi People.Vaccines · 2021Article
- Primary Healthcare in Saudi Arabia: An Evaluation of Emergent Health Trends.Global journal on quality and safety in healthcare · 2021Article
- Middle East Respiratory Syndrome (MERS) Virus-Pathophysiological Axis and the Current Treatment Strategies.AAPS PharmSciTech · 2021Review
- SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV-2) INFECTION: AN EPIDEMIOLOGICAL REVIEW.Annals of Ibadan postgraduate medicine · 2021Article
- Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.Applied biochemistry and biotechnology · 2021Article
- Viral Vectors for COVID-19 Vaccine Development.Viruses · 2021Review
- MERS-CoV: epidemiology, molecular dynamics, therapeutics, and future challenges.Annals of clinical microbiology and antimicrobials · 2021Review
- Decoding Covid-19 with the SARS-CoV-2 Genome.Current genetic medicine reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Middle East respiratory syndrome (MERS) is proposed to be a zoonotic disease. Dromedary camels have been implicated due to reports that some confirmed cases were exposed to camels. Risk factors for MERS coronavirus (MERS-CoV) infections in humans are incompletely understood. This study aimed to describe the demographic characteristics, mortality rate, clinical manifestations and comorbidities with confirmed cases of MERS-CoV.
methodsRetrospective chart review were performed to identify all laboratory-confirmed cases of MERS-CoV in Saudi Arabia who reported to the Ministry of Health (MOH) of Saudi Arabia and WHO between April 23, 2014 and August 31, 2015. Patients' charts were also reviewed for demographic information, mortality, comorbidities, clinical presentations, health care facility and presented with descriptive and comparative statistics using non parametric binomial test and Chi-square test.
resultsConfirmed cases of male patients (61.1%) exceeded those of female patients (38.9%). Infections among Saudi patients (62.6%) exceeded those among non-Saudi patients (37.4%; P = 0.001). The majority of the patients were aged 21-40 years (37.4%) or 41-60 years (35.8%); 43 (22.6%) were aged >61 years, and (8) 4.2% were aged 0-20 years. There was a difference in mortality between confirmed MERS-CoV cases (63.7% alive versus 36.3% dead cases, respectively). Furthermore, fever with cough and shortness of breath (SOB) (n = 39; 20.5%), fever with cough (n = 29; 15.3%), fever (n = 18; 9.5%), and fever with SOB (n = 13; 6.8%), were the most common clinical manifestations associated with confirmed MERS-CoV cases.
conclusionMERS-CoV is considered an epidemic in Saudi Arabia. The results of the present study showed that the frequency of cases is higher among men than women, in Saudi patients than non-Saudi, and those between 21 to 60 years are most affected. Further studies are required to improve the surveillance associated with MERS-CoV to get definite and clear answers and better understanding of the MERS-CoV outbreak as well the source, and route of infection transmission in Saudi Arabia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.